Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

This was the stock's third consecutive day of gains.

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...

Vertex Global Services partners with UK-based Arish Global Services to create over 5,000 jobs in India, boosting the ...

US-based business process management firm Vertex Global Services on Monday announced its partnership with UK-based ...